

Interim Report

MeVis Medical Solutions AG H1-2025/2026



MeVis

TABLE OF CONTENTS

FOREWORD BY THE EXECUTIVE BOARD	2
THE MEVIS SHARE	3
INTERIM MANAGEMENT REPORT H1 2025/2026	4
Preliminary Remarks	4
Company Overview	4
Organization	4
Brief Overview of the Business Activities of	4
Financial Report	5
Business Performance	5
Profitability	5
Financial Position	6
Opportunities and Risks Report	6
Forecast Report	7
BALANCE SHEET	8
STATEMENT OF INCOME	10
NOTES	11
Basic Information	11
General Information	11
Accounting and Valuation Methods	11
Selected Notes on the Balance Sheet and the Income Statement	11
1. Receivables and Other Assets	11
2. Provisions	11
3. Liabilities	12
4. Deferred Income	12
5. Revenue	12
6. Other operating income	12
7. Personnel Expenses	12
8. Other operating expenses	12
9. Related-party transactions	12
Supplementary Report	13
STATEMENT BY THE LEGAL REPRESENTATIVE	14
DISCLAIMER	15

FOREWORD BY THE EXECUTIVE BOARD

Dear Shareholders, Ladies and Gentlemen,

In the first half of the year, total revenue fell short of our expectations: the Company's revenue amounted to €7,861 thousand (previous year: €8,438 thousand). Of this, 32% (previous year: 22%) to the sale of licenses, 32% (previous year: 34%) to maintenance revenue, and 36% (previous year: 44%) to other revenue, which includes, among other things, services provided to and charges passed on to affiliated companies and the parent company. Earnings before interest and taxes (EBIT) fell from €1,853 thousand to €160 thousand, primarily due to lower revenue compared to the previous year, as well as the consolidation of the former joint venture MeVis Breast Care GmbH & Co. KG and the resulting increase in personnel expenses. The EBIT margin is thus 2% (previous year: 22%).

The decline in revenue compared to the same period last year is attributable to subdued license sales to date in the lung screening segment and slightly weaker license sales in the mammography segment. We had anticipated a slight decline in license revenue in mammography; however, other revenue from Hologic—namely maintenance and development services—is slightly better than budgeted. Unfortunately, due to political crises and the unpredictable outlook, the expected revenue in the Middle East, among other regions, could not be realized. Fortunately, the mammography business as a whole, including our two major customers Hologic and Siemens, remained largely stable in the first half of the year despite the global crises, which are also affecting the major medical technology companies.

The revenue forecast for our lung cancer screening solutions remains promising. While license revenue is higher than in the previous year, it is below our original assumptions. The success of the new SaaS (Software as a Service) business model depends on its implementation in the U.S. as well as, to a significant extent, on the rollout of lung cancer screening in Germany, which is officially scheduled to begin in April 2026 but will be delayed by several months in practice. More and more countries are recognizing the need for early detection and are beginning to issue tenders for their nationwide lung cancer screening programs. At the same time, however, we are also observing that an increasing number of medical technology companies are focusing on solutions for lung cancer early detection, bringing products to market, and thus intensifying competition in this sector. Here, we will specifically intensify our marketing and sales activities to promote our products effectively.

The liver diagnostics and liver surgery solutions segment also performed well in the first half of 2025/2026. We are seeing increased demand for both MeVis's proprietary software application, MeVis LiverSuite, and MeVis's proprietary service, MeVis Distant Services. In addition to the U.S. market, which is very important to us, we plan to expand our activities here to major markets such as the Middle East and India.

Based on the results for the first half of the year, current business performance, and the slightly uncertain outlook, we are adjusting our forecast at this time as follows: For the 2025/2026 fiscal year, we now expect slightly higher revenue compared to the previous year, in the range of €16.5 million to €17.0 million (previous forecast: €17.5 million to €18.0 million). We expect lower revenue due to the currently subdued demand in the mammography sector for our customer Hologic, as well as lower revenue due to the delayed implementation of lung cancer screening in Germany. Consequently, we expect earnings before interest and taxes (EBIT) for the 2025/2026 fiscal year to be between €0.5 million to €1.0 million (previous forecast: €1.0 million to €1.5 million), assuming a stable exchange rate of 1.16 USD/EUR. The Management Board will regularly review its expectations during the 2025/2026 fiscal year based on current business developments.


Marcus Kirchhoff
Member of the Executive Board

THE MEVIS SHARE

AS OF MARCH 31, 2026	
ISIN / WKN / Ticker Symbol	DE000A0LBFE4 / A0LBFE / M3V
Industry Classification	Software / Medical Technology
Paid-in share capital	€ 1,820,000.00
Number of shares	1,820,000
Last price quote on September 30, 2025	€ 24.80
Last price on March 31, 2026	€ 22.40
High/Low price in FY 2025/2026	€26.40 / €22.20
Market capitalization	€40.768 million
General Standard (Regulated Market)	Frankfurt and Xetra
Over-the-Counter	Berlin, Düsseldorf, Munich, Stuttgart
Indices	CDAX, General All-Share, DAXsector All Software

SHARE PRICE HISTORY

From October 1, 2025, to March 31, 2026, the MeVis Medical Solutions AG share traded at an average price of approximately €24.90. At the start of the fiscal year, the share was trading at €24.80 and closed at €22.40 in Xetra trading at the end of March. During the first half of the 2025/2026 fiscal year, the share's high in Xetra trading was €26.40 and the low was €22.20. Compared to €26.00 at the end of March 31, 2025, the value of the MeVis share has fallen by 14% over twelve months. As of March 31, 2026, the market capitalization was therefore approximately €41 million, based on 1,820,000 shares outstanding.

SHAREHOLDER STRUCTURE AS OF MARCH 31, 2026

As of the balance sheet date, 73.66% of the total share capital of MeVis Medical Solutions AG was held by Varex Imaging Deutschland AG, an indirect subsidiary of Varex Imaging Corporation, Salt Lake City, Utah, USA. According to shareholder notifications received by us, another institutional shareholder is HANSAINVEST Hanseatische Investment-GmbH, holding approximately 12.57% of the total share capital of MeVis Medical Solutions AG. Consequently, approximately 13.77% of the shares are in free float.

COMPENSATION PAYMENT

The control and profit transfer agreement between Varex Imaging Deutschland AG and MeVis Medical Solutions AG obligates Varex Imaging Deutschland AG to pay the minority shareholders a recurring cash payment ("equalization payment") for each full fiscal year for the duration of this agreement. This amounts to €1.13 (gross) or €0.95 (net) per share for each full fiscal year.

INTERIM MANAGEMENT REPORT H1 2025/2026

PRELIMINARY REMARKS

This report covers the first half of the 2025/2026 fiscal year, i.e., the reporting period from October 1, 2025, to March 31, 2026. The prior-year figures provided below refer to the first half of the 2024/2025 fiscal year, from October 1, 2024, to March 31, 2025. MeVis Medical Solutions AG prepared its annual financial statements for the 2024/2025 fiscal year in accordance with the provisions of the German Commercial Code (HGB) applicable to corporations and in compliance with the German Stock Corporation Act. These interim financial statements were also prepared on this basis.

COMPANY OVERVIEW

ORGANIZATION

MeVis Medical Solutions AG (hereinafter also "MMS AG," "MeVis," or "the Company") was founded in 1997 and commenced business operations in 1998. 73.66% of the share capital of MeVis Medical Solutions AG is currently held by Varex Imaging Deutschland AG, Walluf. A control and profit transfer agreement exists between Varex Imaging Deutschland AG, as the controlling company, and MeVis Medical Solutions AG, as the controlled company. MeVis Medical Solutions AG thus belongs, via Varex Imaging Deutschland AG, to the Varex Group under the leadership of Varex Imaging Corporation, Salt Lake City, Utah, USA.

As of the end of the 2024/2025 fiscal year, Varex Imaging Deutschland AG, MeVis Medical Solutions AG, and MeVis BreastCare Verwaltungsgesellschaft mbH are the sole shareholders of MeVis BreastCare GmbH & Co. KG (hereinafter also "MBC KG"). As part of a strategic business decision, Varex Imaging Corporation has decided not to continue the existing joint venture. To this end, the limited partner Varex Imaging Deutschland AG and MeVis BreastCare Verwaltungsgesellschaft mbH have withdrawn from MeVis BreastCare GmbH & Co. KG effective as of October 31, 2025. The company is thus dissolved and terminated as of the effective date of withdrawal. The company's assets have been transferred to the sole remaining limited partner, MeVis Medical Solutions AG. MeVis BreastCare Verwaltungsgesellschaft mbH was merged in its entirety, with all rights and obligations, into MeVis Medical Solutions AG pursuant to a merger agreement dated March 12, 2026, retroactive to October 1, 2025. All customer relationships, employees, and projects of MeVis BreastCare GmbH & Co. KG will be continued within MeVis Medical Solutions AG.

BRIEF OVERVIEW OF THE BUSINESS ACTIVITIES OF

MeVis Medical Solutions AG develops innovative software for the acquisition, analysis, and evaluation of image data and markets it to medical device manufacturers, providers of medical IT platforms, as well as directly to clinical end customers.

The clinical focus is on image-based early detection and diagnosis of epidemiologically significant diseases, such as breast, lung, and liver diseases. The software solutions support many imaging modalities in use. These include not only X-ray-based radiography modalities such as computed tomography, mammography, and digital tomosynthesis, but also magnetic resonance imaging, digital sonography, and the simultaneous use of multiple modalities (multimodality). MeVis provides global market leaders in the medical industry with technologies and software applications that meet these companies' demands for technological leadership and help them expand their market position.

In addition to selling software licenses, along with associated maintenance contracts, and offering our software solutions as a subscription model or SaaS (Software as a Service), MeVis also provides software programming services for medical technology companies as development services. These include project management by software development teams consisting of software developers, product and project managers, application specialists, and test engineers. The teams support external clients in the development of software modules or applications and in the integration of new features and technologies, such as algorithms based on artificial

intelligence. Services are also provided to clinical end customers. These include, among other things, three-dimensional technical visualizations (“MeVis Distant Services”), interactive online training to improve clinicians’ diagnostic skills, and internet-based specialized applications in teleradiology (“MeVis Online Services”).

While MeVis initially focused on image-based early detection and diagnosis of breast cancer, the company now leverages its accumulated clinical expertise, know-how in the field of breast cancer, innovative software technologies, and established partner network to continuously refine its software solutions and develop new applications for other indications and diseases affecting other parts of the body.

FINANCIAL REPORT

BUSINESS PERFORMANCE

The Company’s operating business consists of the development and sale of software licenses, the associated maintenance business, software programming for medical technology companies (development services), and the provision of services for technical visualizations (Distant Services) as well as online training.

Accounting for approximately 89% (previous year: 85%) of total revenue, the software business, which includes products for medical technology companies such as Hologic and Siemens, continued to contribute the majority of the company’s total revenue in this reporting period.

The first half of the 2025/2026 fiscal year was unsatisfactory for MeVis in terms of financial metrics. While the company was able to benefit from Hologic’s strong market position in breast cancer screening and from demand for lung cancer screening, we fell short of our own revenue expectations. The partial transition of our business model from a pure licensing model to a subscription model (SaaS), as well as lower customer demand, particularly in the Middle East, contributed to lower revenue.

PROFITABILITY

In the first half of the year, the company’s revenue totaled €7,861 thousand (previous year: €8,438 thousand). Revenue was attributable 32% (previous year: 22%) to the sale of licenses, 32% (previous year: 34%) to maintenance revenue, and 36% (previous year: 44%) to other revenue, which includes, among other things, services provided to and charges passed on to affiliated companies and the parent company. The percentage increase in license revenue is attributable to the business acquired from Siemens following the merger of MBC KG into the Company, while the slight decline in maintenance revenue stems from business with various customers.

Other operating income amounted to €696 thousand in the first half of the year (previous year: €1,233 thousand). It consists primarily of income from exchange rate differences in the amount of €498 thousand (previous year: €1,188 thousand). Other operating income includes income of €129 thousand from the amalgamation of MBC KG. Cost of materials decreased to €154 thousand (previous year: €188 thousand). The Company’s personnel expenses amounted to €6,508 thousand in the first half of the year (previous year: €5,307 thousand).

During the reporting period, the average number of permanent employees increased by 13 to 123 due to the consolidation of MBC KG.

Other operating expenses amounted to €1,661 thousand in the reporting period (previous year: €2,250 thousand). They consist of foreign exchange losses of €356 thousand (previous year: €1,025 thousand), rent expenses of €324 thousand (previous year: €268 thousand), legal, consulting, and audit fees of €286 thousand (previous year: €287), sales expenses of €85 thousand (previous year: €100 thousand), operating expenses of €79 thousand (previous year: €98 thousand), and other operating expenses of €531 thousand (previous year: €469 thousand).

Earnings before interest and taxes (EBIT) fell from €1,853 thousand to €160 thousand, primarily due to lower sales revenue compared to the previous year and increased personnel expenses.

Income from loans under financial assets amounted to €492 thousand (previous year: €550 thousand) and consisted of interest income from the loan granted to Varex Imaging Deutschland AG. This results in earnings before taxes (EBT) of €669 thousand (previous year: €2,468 thousand).

In the past six months, income taxes of €47 thousand (previous year: €65 thousand) were incurred; therefore, taking into account the expense from the transfer of earnings to Varex Imaging Deutschland AG in the amount of €622 thousand (previous year: €2,404 thousand), net income for the period amounts to €0 thousand (previous year: €0 thousand). It should be noted that the expense from the transfer of earnings does not legally arise until the end of the fiscal year.

FINANCIAL POSITION

Total assets decreased to €23,162 thousand (September 30, 2025: €25,886 thousand). On the assets side, current assets decreased by €2,568 thousand. Equity remained unchanged. On the liabilities side, provisions decreased by €138 thousand and liabilities by €2,705 thousand. In contrast, deferred income increased by €119 thousand. As part of the expansion of MBC KG, assets totaling €984 thousand were transferred to the company, of which €831 thousand consisted of trade receivables. At the same time, liabilities of €452 thousand were assumed, primarily relating to other provisions (€385 thousand).

The equity ratio increased to 77% (September 30, 2025: 69%) due to the decrease in total assets and constant equity. The debt-to-equity ratio decreased accordingly to 23% (September 30, 2025: 31%).

Current assets decreased by €2,568 thousand to €6,389 thousand as of the balance sheet date (September 30, 2025: €8,957 thousand). This is primarily attributable to the decrease in cash and cash equivalents (cash on hand, bank balances) from €6,542 thousand to €3,649 thousand.

The Company's equity remained constant at €17,826 thousand (September 30, 2025: €17,826) and consists, in addition to the subscribed capital of €1,820 (September 30, 2025: €1,820), of the capital reserve of €11,461 (September 30, 2025: €11,461 thousand) as well as statutory retained earnings of €5 thousand (September 30, 2025: €5 thousand) and other retained earnings of €4,540 thousand (September 30, 2025: €4,540 thousand).

Provisions decreased by €138 thousand compared to the previous year, to €2,202 thousand (September 30, 2025: €2,340 thousand). Pension provisions increased from €227 thousand to €256 thousand due to the amalgamation of MBC KG. Other provisions decreased to €1,946 thousand, partly due to lower personnel provisions. Liabilities decreased by €2,705 thousand to €1,476 thousand (September 30, 2025: €4,181 thousand), primarily due to the reduction in liabilities to affiliated companies. Deferred income increased by €119 thousand to €1,658 thousand due to higher customer prepayments for services to be rendered by the Company in the future compared to the previous year. The Company's cash and cash equivalents decreased by €2,874 thousand to €3,649 thousand in the first half of the year.

Overall, the Company's net assets, financial position, and results of operations remain satisfactory.

OPPORTUNITIES AND RISKS REPORT

Since the beginning of the fiscal year, there have been no significant changes in the Company's risk profile. The information in the opportunities and risks report of the financial statements as of the end of the fiscal year, September 30, 2025, therefore remains valid.

FORECAST REPORT

Based on the results for the first half of the year, current business performance, and the somewhat uncertain outlook, we are adjusting our forecast at this time as follows: For the 2025/2026 fiscal year, we now expect slightly higher revenue compared to the previous year, in the range of €16.5 million to €17.0 million (previous forecast: €17.5 million to €18.0 million). We expect lower revenue due to the currently subdued demand in the mammography sector for our customer Hologic, as well as lower revenue due to the delayed implementation of lung cancer screening in Germany. Consequently, we expect earnings before interest and taxes (EBIT) for the 2025/2026 fiscal year to be between €0.5 million to €1.0 million (previous forecast: €1.0 million to €1.5 million), assuming a stable exchange rate of 1.16 USD/EUR. The Management Board will regularly review its expectations during the 2025/2026 fiscal year based on current business developments

As in the previous reporting period, the Management Board will regularly review its expectations during the 2025/2026 fiscal year based on current business developments.

Bremen, May 21, 2026



Marcus Kirchoff
Sole Member of the Executive Board

BALANCE SHEET

of MeVis Medical Solutions AG, Bremen, as of March 31, 2026

ASSETS (AMOUNTS IN €)	March 31, 2026	09/30/2025
A. Fixed assets		
I. Intangible Assets		
Concessions, industrial property rights, and similar rights and assets acquired for consideration, as well as licenses to such rights and assets	0.00	0.00
II. Property, plant, and equipment		
Furniture and equipment	294,119.06	308,772.16
III. Financial assets		
1. Shares in affiliated companies	0.00	299,805.00
2. Loans to affiliated companies	16,225,211.69	16,225,211.69
	16,225,211.69	16,525,016.69
	16,519,330.75	16,833,788.85
B. Current assets		
I. Receivables and other assets		
1. Trade receivables services	1,984,451.25	1,513,982.95
2. Receivables from affiliated companies	490,700.78	668,842.46
3. Other assets	264,782.89	250,093.35
	2,739,934.92	2,432,918.76
II. Cash on hand, balances with financial institutions	3,649,320.34	6,524,209.93
	6,389,255.26	8,957,128.69
C. Prepaid expenses and deferred charges	253,893.46	95,480.94
	23,162,479.47	25,886,398.48

LIABILITIES (AMOUNTS IN €)	March 31, 2026	September 30, 2025
A. Equity		
I. Subscribed capital	1,820,000.00	1,820,000.00
II. Capital reserve	11,461,332.48	11,461,332.48
III. Retained earnings		
1. Statutory reserve	5,000.00	5,000.00
2. Other retained earnings	4,539,688.30	4,539,688.30
	<u>4,544,688.30</u>	<u>4,544,688.30</u>
	<u>17,826,020.78</u>	<u>17,826,020.78</u>
B. Provisions		
1. Provisions for pensions and similar obligations obligations	256,329.00	226,606.00
2. Tax provisions	0.00	876.86
3. Other provisions	1,945,939.90	2,112,897.51
	<u>2,202,268.90</u>	<u>2,340,380.37</u>
C. Liabilities		
1. Advance payments received on orders	522,733.70	709,459.78
2. Trade payables	75,395.97	143,656.43
3. Liabilities to affiliated companies	668,310.49	3,165,924.23
4. Other liabilities	209,993.22	161,999.15
	<u>1,476,433.38</u>	<u>4,181,039.59</u>
D. Prepaid expenses and deferred charges	<u>1,657,756.41</u>	<u>1,538,957.74</u>
	<u>23,162,479.47</u>	<u>25,886,398.48</u>

STATEMENT OF INCOME

of MeVis Medical Solutions AG, Bremen, for the period from October 1, 2025, to March 31, 2026 (prior year: October 1, 2024 to March 31, 2025)

FIGURES IN €	2025/2026	2024/2025
1. Revenue	7,861,021.77	8,438,363.57
2. Other operating income	696,159.51	1,233,487.44
3. Cost of materials		
a) Cost of goods purchased	64,440.00	33,608.13
b) Expenses for purchased services	<u>89,348.34</u>	<u>154,688.42</u>
	153,788.34	188,296.55
4. Personnel expenses		
a) Wages and salaries	5,399,555.81	4,434,751.26
b) Social security contributions and expenses for pensions and support	<u>1,108,143.16</u>	<u>871,826.17</u>
	6,507,698.97	5,306,577.43
5. Amortization of intangible assets and depreciation of property, plant, and equipment	75,131.64	73,882.29
6. Other operating expenses	1,661,036.03	2,250,284.98
7. Income from loans of financial assets	492,367.42	549,928.63
8. Other interest and similar income	17,128.06	65,637.55
9. Income taxes	<u>47,015.43</u>	<u>64,875.44</u>
10. Net income	622,006.35	2,403,500.50
11. Profit to be transferred pursuant to a profit transfer agreement	<u>622,006.35</u>	<u>2,403,500.50</u>
12. Net income for the period	<u>0.00</u>	<u>0.00</u>

NOTES

to the semi-annual financial report of MeVis Medical Solutions AG, Bremen,
as of March 31, 2026

BASIC INFORMATION

GENERAL INFORMATION

MeVis Medical Solutions AG is headquartered at Caroline-Herschel-Straße 1 in 28359 Bremen, Germany, and is registered in the Commercial Register of the Bremen Local Court (HRB 23791 HB).

73.66% of the share capital of MeVis Medical Solutions AG is currently held by Varex Imaging Deutschland AG, Walluf. A control and profit transfer agreement exists between Varex Imaging Deutschland AG, as the controlling company, and MeVis Medical Solutions AG, as the controlled company. MeVis Medical Solutions AG thus belongs, via Varex Imaging Deutschland AG, to the Varex Group under the leadership of Varex Imaging Corporation, Salt Lake City, Utah, USA.

MeVis Medical Solutions AG prepared its annual financial statements for the 2024/2025 fiscal year in accordance with the provisions of the German Commercial Code (HGB) applicable to corporations and in compliance with the German Stock Corporation Act. These interim financial statements were also prepared on this basis. These interim financial statements have not been subject to a review or audit in accordance with Section 317 of the German Commercial Code (HGB).

ACCOUNTING AND VALUATION METHODS

The same accounting and valuation methods were applied in the preparation of the interim financial statements and the determination of the comparative figures for the prior year as in the 2024/2025 annual financial statements. A detailed description of these methods is published in the notes to the 2024/2025 annual financial statements.

SELECTED NOTES ON THE BALANCE SHEET AND THE INCOME STATEMENT

1. RECEIVABLES AND OTHER ASSETS

Trade receivables amounted to €1,984 thousand as of the balance sheet date (September 30, 2025: €1,514 thousand) and primarily relate to receivables from customers Hologic, Varian Medical Systems, and Siemens. All receivables have a remaining term of up to one year.

Receivables from affiliated companies amount to €491 thousand (September 30, 2025: €615 thousand) and relate to transactions with Varex Imaging Corporation, Salt Lake City, USA.

Other assets amounted to €265 thousand as of the balance sheet date (September 30, 2025: €250 thousand). These primarily relate to a rental deposit of €250 thousand (previous year: €250 thousand).

2. PROVISIONS

Other provisions amount to €1,946 thousand (September 30, 2025: €2,113 thousand). Of this amount, €473 thousand (September 30, 2025: €347 thousand) relates to provisions for vacation and overtime, €387 thousand (September 30, 2025: €505 thousand) to provisions for bonuses, €352 thousand (September 30, 2025: €277 thousand) to warranty provisions, €310 thousand (September 30, 2025: €352 thousand) to outstanding invoices, and €191 thousand (September 30, 2025: €328 thousand) to provisions for the 13th-month salary.

3. LIABILITIES

During the reporting period, trade payables decreased by €68 thousand and amounted to €75 thousand as of the reporting date. Liabilities to affiliated companies in the amount of €668 thousand (September 30, 2025: €3,166 thousand) relate primarily to the profit transfer under the existing control and profit transfer agreement with Varex Imaging Deutschland AG. The liability does not arise legally until the end of the 2025/2026 fiscal year.

4. DEFERRED INCOME

This item includes deferred revenue components from multi-component contracts that have already been paid but not yet recognized. In addition, payments received from maintenance contracts are deferred to the extent that the corresponding maintenance services have not yet been performed.

5. REVENUE

Revenue is broken down into the following revenue categories:

AMOUNTS IN THOUSANDS OF €	October 1, 2025 – March 31, 2026	Oct. 1, 2024 – Mar. 31, 2025
Services (Consulting and Training)	2,839	3,701
Maintenance (software service contracts)	2,527	2,910
Software and licenses	2,495	1,827
	7,861	8,438

6. OTHER OPERATING INCOME

Other operating income amounted to €696 thousand in the first half of the year (previous year: €1,233 thousand). Of this amount, €498 thousand (previous year: €1,188 thousand) is attributable to exchange rate differences, which result from the fact that the majority of services are invoiced in U.S. dollars and liquidity is also held in U.S. dollars. Due to the Company's affiliation with the Varex Imaging Group and in accordance with its corporate policy, no hedging transactions are entered into.

Other operating income includes income of €129 thousand from the amalgamation of MBC KG.

7. PERSONNEL EXPENSES

On average, 127 employees (same period last year: 114) were employed, of whom 123 were permanent employees (same period last year: 110). This corresponds to an average of 110 full-time equivalents (same period last year: 100). The increase results from the amalgamation of MBC KG.

8. OTHER OPERATING EXPENSES

Other operating expenses amounted to €1,661 thousand in the reporting period (previous year: €2,250 thousand). They consist of expenses from exchange rate differences in the amount of €356 thousand (previous year: €1,025 thousand), rent expenses in the amount of €324 thousand (previous year: €268 thousand), expenses for legal, consulting, and auditing services in the amount of €286 thousand (previous year: €287), sales expenses of €85 thousand (previous year: €100 thousand), operating expenses of €79 thousand (previous year: €98 thousand), and other operating expenses of €531 thousand (previous year: €469 thousand).

9. RELATED-PARTY TRANSACTIONS

The Company enters into transactions with related parties, which are described below. These transactions are part of the Company's ordinary course of business and are treated in the same manner as transactions with unrelated third parties.

Related parties and companies include Varex Imaging Deutschland AG and, through it, the affiliated companies of the Varex Group, as well as the Management Board and the Supervisory Board and their close relatives.

The following receivables, liabilities, expenses, and revenues of the Company relate to related parties:

AMOUNTS IN THOUSANDS OF €	2025/2026
Parent Company	
Receivables (from loans granted)	16,225
Liabilities (from profit transfer agreement)	622
Revenue (primarily from services and interest income)	851
Expenses (from profit transfer agreement)	622
Other Affiliated Companies	
Receivables (from services)	491
Liabilities (from services)	46
Revenue (from services)	880
Expenses (from services)	128

SUPPLEMENTARY REPORT

No business transactions of particular significance to the company have occurred since the balance sheet date.

STATEMENT BY THE LEGAL REPRESENTATIVE

"I hereby certify to the best of my knowledge that, in accordance with the applicable accounting principles for interim financial reporting, the interim financial statements of MeVis Medical Solutions AG present a true and fair view of the financial position, financial position, and results of operations of MeVis Medical Solutions AG, and that the interim management report presents the course of business, including the business results and the situation of MeVis Medical Solutions AG, in such a way as to provide a true and fair view, and describes the significant opportunities and risks associated with the expected development of MeVis Medical Solutions AG for the remainder of the fiscal year."

Bremen, May 21, 2026

MeVis Medical Solutions AG



Marcus Kirchhoff
Sole Member of the Executive Board

DISCLAIMER

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements based on management's current assessments of future developments. Such statements are subject to risks and uncertainties that are beyond the control of MeVis Medical Solutions AG or that the company cannot accurately assess, such as the future market environment and economic conditions, the behavior of other market participants, the successful integration of new acquisitions, and actions taken by government authorities. Should any of these or other uncertainties and risks materialize, or should the assumptions on which these statements are based prove to be incorrect, actual results could differ materially from those explicitly stated or implicitly contained in these statements. MeVis Medical Solutions AG neither intends nor assumes any separate obligation to update forward-looking statements to reflect events or developments after the date of this report.

DISCREPANCIES DUE TO TECHNICAL REASONS

For technical reasons (e.g., conversion of electronic formats), there may be discrepancies between the financial statements contained in this financial report and those filed with the Federal Gazette. In such cases, the version filed with the Federal Gazette shall be deemed the authoritative version.

The financial report is also available in English translation; in the event of discrepancies, the German version takes precedence over the English translation.

The financial report is already available for download on the Internet at:

<http://www.mevis.de/de/investor-relations/finanzberichte/>

MeVis Medical Solutions AG

Caroline-Herschel-Str. 1
28359 Bremen
Germany

Phone +49 421 22495 0

Fax +49 421 22495 999

info@mevis.de

www.mevis.de